Though single-agent therapies against IGF-1R or mTOR have proved ineffective in osteosarcoma, the ability to co-target these pathways using novel biologically-targeted agents would be expected to yield synergistic anti-cancer activity, as has been observed in preclinical bone sarcoma models [53]. This evidence concerns the gene MTOR and osteosarcoma.